Johnson & Johnson Files NDA For Oral Analgesic Tapentadol
This article was originally published in The Pink Sheet Daily
Executive Summary
Filing gives tapentadol a Nov. 22 user fee date with standard review.
You may also be interested in...
J&J's Phase III Tapentadol Beats Oxycodone Side Effects
Outlined studies include foot-surgery pain.
J&J's Phase III Tapentadol Beats Oxycodone Side Effects
Outlined studies include foot-surgery pain.
J&J Pipeline On Track; Tapentadol Filing Expected This Week
Firm reports fourth quarter pharmaceutical sales of $6.4 billion worldwide and $3.9 billion in the U.S.